SCHEMBL7488206

SCHEMBL7488206

O=C(Nc1ccccc1)Nc1ccc(F)c(F)c1O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.63
MEN1 O00255 5/20 0.63
SMN1; SMN2 Q16637 6/20 0.60
NPC1 O15118 6/20 0.60
RAB9A P51151 6/20 0.60
HTT P42858 5/20 0.60
LMNA P02545 4/20 0.57
ALDH1A1 P00352 1/20 0.57
TP53 P04637 1/20 0.55
EPHX1 P07099 1/20 0.55
TSHR P16473 1/20 0.55
EPHX2 P34913 1/20 0.55
CDK9 P50750 1/20 0.55
CLK4 Q9HAZ1 1/20 0.55
CXCR2 P25025 4/20 0.52
MAPT P10636 3/20 0.52
MAOA P21397 1/20 0.51
MAOB P27338 1/20 0.51
POLB P06746 1/20 0.51
CXCR1 P25024 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31304857 0.87 KMT2A (0.72) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL4348999 0.82 KMT2A (0.70) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL5594682 0.81 HTT (0.67) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL4344475 0.81 RAB9A (0.57) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL7139590 0.79 KMT2A (0.66) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL21834403 0.78 NPC1 (0.81) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL24272365 0.77 SMN1; SMN2 (0.74) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL29757933 0.77 SMN1; SMN2 (0.74) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL4341436 0.76 SMN1; SMN2 (0.68) KMT2AMEN1SMN1; SMN2NPC1RAB9A
SCHEMBL4350139 0.76 SMN1; SMN2 (0.63) KMT2AMEN1SMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0896531-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-10-30 EP disclosed
US-20020128321-A1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2002-09-12 US disclosed
US-6262113-B1 HYDROXY- OR MERCAPTO-PHENYLUREAS SMITHKLINE BEECHAM CORPORATION 2001-07-17 US disclosed
US-6211373-B1 Phenyl urea antagonists of the IL-8 receptor SMITHKLINE BEECHAM CORPORATION 2001-04-03 US disclosed
EP-0896531-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-17 EP disclosed
US-5780483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1998-07-14 US disclosed
WO-1997029743-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128321-A1 IL-8 receptor antagonists CXCL8, CCR8, IL1RN KMT2A 3978/4885MEN1 4754/4885SMN1; SMN2 4507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.